Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Epidemiology of Pediatric Invasive Group A Streptococcal Infections in 10 US States, 2004-2023.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramachandran Veena, Onukwube Okaro Jennifer, Prasad Namrata, Park Soyoun, McGee Lesley, Chochua Sopio, Li Yuan, Anderson Bridget J, Burzlaff Kari E, Harrison Lee H, Carter Terresa, Houston Jessica, Sosin Daniel M, Fails Kayla, Zipprich Jennifer, Petit Susan, Rosales Maria, Chai Shua J, Schaffner William, Markus Tiffanie M, Thomas Ann, Martin Tasha, Tunali Amy, Howard-Anderson Jessica, Barnes Meghan, Youngkin Erin, Gregory Christopher J
Аннотация
BACKGROUND: Group A Streptococcus (GAS) infections are common in children, ranging from mild to life-threatening invasive disease. Large-scale descriptions of changes in pediatric invasive GAS infections in the United States, particularly during the coronavirus disease 2019 (COVID-19) pandemic, are limited.
METHODS: We used the Centers for Disease Control and Prevention's (CDC's) Active Bacterial Core surveillance (ABCs), a multistate, population- and laboratory-based surveillance system, to assess changes in pediatric (<18 years old) invasive GAS incidence, clinical presentation, and bacterial strain characteristics from 2004 to 2023. Interrupted time series analysis was used to compare observed versus expected GAS incidence during 2020-2023, informed by trends before the COVID-19 pandemic (2004-2019).
RESULTS: During 2004-2023, 2856 invasive GAS cases were identified. Incidence remained stable from 2004 to 2019 (mean incidence 1.9 per 100 000), decreased in 2020 (1.0) and 2021 (0.6), and rebounded in 2022 (1.5) and 2023 (4.4). ICU admission increased from 2011 to 2023; case fatality remained stable. Penicillin resistance was not detected. Clindamycin non-susceptibility doubled from 2011 (3.8%) to 2022 (7.5%), before slightly decreasing in 2023 (6.4%). Infections due to emm1, the most frequently identified emm type in children with severe disease, almost disappeared in 2021 but surged in late 2022.
CONCLUSIONS: After remaining stable for more than a decade, pediatric invasive GAS incidence declined during the COVID-19 pandemic and rebounded in 2022, more than doubling 2004-2019 incidence in 2023. Although case fatality remained low, intensive care unit (ICU) admissions increased over time, highlighting the need for effective preventive measures such as vaccines. Increasing clindamycin non-susceptibility bears continued monitoring.
METHODS: We used the Centers for Disease Control and Prevention's (CDC's) Active Bacterial Core surveillance (ABCs), a multistate, population- and laboratory-based surveillance system, to assess changes in pediatric (<18 years old) invasive GAS incidence, clinical presentation, and bacterial strain characteristics from 2004 to 2023. Interrupted time series analysis was used to compare observed versus expected GAS incidence during 2020-2023, informed by trends before the COVID-19 pandemic (2004-2019).
RESULTS: During 2004-2023, 2856 invasive GAS cases were identified. Incidence remained stable from 2004 to 2019 (mean incidence 1.9 per 100 000), decreased in 2020 (1.0) and 2021 (0.6), and rebounded in 2022 (1.5) and 2023 (4.4). ICU admission increased from 2011 to 2023; case fatality remained stable. Penicillin resistance was not detected. Clindamycin non-susceptibility doubled from 2011 (3.8%) to 2022 (7.5%), before slightly decreasing in 2023 (6.4%). Infections due to emm1, the most frequently identified emm type in children with severe disease, almost disappeared in 2021 but surged in late 2022.
CONCLUSIONS: After remaining stable for more than a decade, pediatric invasive GAS incidence declined during the COVID-19 pandemic and rebounded in 2022, more than doubling 2004-2019 incidence in 2023. Although case fatality remained low, intensive care unit (ICU) admissions increased over time, highlighting the need for effective preventive measures such as vaccines. Increasing clindamycin non-susceptibility bears continued monitoring.